Karuna Therapeutics — Technical Presentation (March 2023)
21 slides from Karuna Therapeutics's technical presentation, Mar 20, 2023
Slide 1: Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia Topline Data Results
Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia Topline Data Results March 20, 2023 Exhibit 99.2
Slide 2: Forward looking statements
Forward looking statements This presentation and other related material may contain a number of “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding Karuna’s expectation about any or all of the following:
Slide 3: Agenda
Introduction Bill Meury President and Chief Executive Officer Phase 3 EMERGENT-3 trial results Steve Brannan, M.D. Chief Medical Officer Building a leading neuroscience company Bill Meury Q&A Agenda 3 Bill Meury Steve Brannan, M.D. Steve Paul, M.D. President of R&D and Chief Scientific Officer Andre
Slide 4: Our purpose
Our purpose is to create and deliver transformative medicines for people living with psychiatric and neurological conditions
Slide 5: Schizophrenia
5 Sources: GBD 2017, Patel et al. 2014, Remington et al. 2016, Goff et al. 2011, Liebermann et al. 2005 One of the leading causes of disability worldwide, with onset in late-teens / early-adulthood 21M+ people living with schizophrenia globally Estimated potential life lost is 10-20 years compared t
Slide 6: Need for new pharmacological approach for treatment of schizophrenia
Up to 30% of patients do not respond to therapy ~50% experience only a partial improvement in positive symptoms or unacceptable side effects ~75% of patients discontinue treatment in the first 18 months 10-15M U.S. prescriptions annually, within 1 class of medicine Need for new pharmacological appro
Slide 7: Phase 3 EMERGENT-3 trial topline results
Phase 3 EMERGENT-3 trial topline results Steve Brannan, M.D. Chief Medical Officer 7
Slide 8: Third positive registrational trial in the EMERGENT program
Third positive registrational trial in the EMERGENT program NDA = New Drug Application; *Additional analyses ongoing EMERGENT-1 NCT03697252 EMERGENT-2 NCT04659161 EMERGENT-3 NCT04738123 EMERGENT-4 NCT04659174 EMERGENT-5 NCT04820309 Phase 2 Phase 3 Phase 3 Phase 3 Phase 3 Efficacy and safety of KarXT
Slide 9: EMERGENT-3 trial design
EMERGENT-3 trial design KarXT dose is expressed as xanomeline/trospium (mg/mg); Reflective of intent to treat (iTT) population *Washout of prior oral lithium and/or antipsychotics; †Optional increase in dose based on tolerability determined by a clinician; ‡Analyses not available at topline data PAN
Slide 10: Demographics and baseline characteristics
Demographics and baseline characteristics *Mean age represented in years; PANSS = Positive & Negative Syndrome Scale ITT population 10 KarXT (n=125) Placebo (n=131) Mean age, n (SD)* 43.6 (11.4) 42.6 (12.2) Sex, n (%) Male Female 87 (69.6) 38 (30.4) 104 (79.4) 27 (20.6) Race, n (%) Asian Black
Slide 11: Primary outcome measure: PANSS total score at Week 5
Primary outcome measure: PANSS total score at Week 5 Cohen’s d effect size of 0.60 GO KARUNA ++ Placebo g oF; 7 —® KarxT SS fF Ree, * p<0.05 g coe ** p<0.01 Bo sf Nt, err D<0,0001 = 3 Eg £4 = o © SD -10 + De ce aoc S§ 3 2-15 f+ £2 8 z -20 + = -25 ! 1 1 1 1 8.4-point reduction in PANSS total score vs
Slide 12: Secondary outcome measure: PANSS positive subscale at Week 5
Secondary outcome measure: PANSS positive subscale at Week 5 - +*@-- Placebo 3 0 ee aT. BH Of p<0.01 5S || Piiiss., °F )<0.001 ~ | oN. #0" NCO, ES fo Nee p<0,0001 ot tee, BM fe ee re o +. as a ss og -4 >e ° ge go 8 -6 z < a -8 1 Baseline Week 2 Week 3 Week 4 Week 5 3.5-point reduction in PANSS-posit
Slide 13: Secondary outcome measure: PANSS negative subscale at Week 5
Secondary outcome measure: PANSS negative subscale at Week 5 vo = 7] wo 8 ti) A En 4H ho -t “a Od $s c $3 -2 Be og po <£ 7) -3 0) z < a -4 1 1 1 n 1 Baseline Week 2 Week 3 Week 4 Week 5 0.8-point reduction in PANSS-negative subscale score vs. placebo at Week 5, p=0.12 (-2.7 KarXT vs. -1.8 placebo) G
Slide 14: Secondary outcome measure: PANSS negative Marder factor subscale at Week 5
Secondary outcome measure: PANSS negative Marder factor subscale at Week 5 +++ Placebo —®KarXxXT (LS mean change) 1 N PANSS negative Marder factor change from baseline -4 5 1 Il 1 1 1 Baseline Week 2 Week 3 Week 4 Week 5 0.8-point reduction in PANSS negative Marder factor suk le score vs. placebo at
Slide 15: KarXT was generally well tolerated, consistent with prior EMERGENT trials
KarXT was generally well tolerated, consistent with prior EMERGENT trials Summary of safety and tolerability of safety population (KarXT n=125, placebo n=128) TEAE = treatment emergent adverse event, GERD = gastroesophageal reflux disease, EPS = extrapyramidal symptoms KarXT was generally well toler
Slide 16: Building a leading neuroscience company
Building a leading neuroscience company Bill Meury 16
Slide 17: Robust antipsychotic effect across three registrational trials
Robust antipsychotic effect across three registrational trials *Cohen’s d is a standardized effect size for measuring the difference between two group means KEY METRICS EMERGENT-3 EMERGENT-2 EMERGENT-1 Primary endpoint PANSS total score KarXT vs. placebo at Week 5 -8.4 (-20.6 KarXT vs. -12.2 placebo
Slide 18: KarXT has the potential to be a completely new and advanced treatment for schizophrenia
18 KarXT has the potential to be a completely new and advanced treatment for people with schizophrenia Novel mechanism of action Early and sustained reduction of positive and negative symptoms of schizophrenia Generally well tolerated, with consistent side effect profile May not be associated with c
Slide 19: KarXT serves as the foundation of our neuroscience pipeline
KarXT serves as the foundation of our neuroscience pipeline *In-licensed KAR-2618 (formerly GFB-887) from assignment estate of Goldfinch Bio in January 2023; currently in planning stage †In collaboration with PsychoGenics COMPOUND INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 NDA SUBMISSION KarXT (
Slide 20: Maintaining momentum with multiple milestones ahead
Maintaining momentum with multiple milestones ahead $1.1 billion in cash expected to fund operations through 2025* *Reflects cash, cash equivalents, and available-for-sale investments as of December 31, 2022; †In-licensed KAR-2618 (formerly GFB-887) from assignment estate of Goldfinch Bio in January
Slide 21: Q&A
Q&A 21
Karuna Therapeutics — Technical Presentation (March 2023) on 6ix